We are dedicated to developing innovative microbiome therapeutics that have the potential to transform lives.
Each day we are working with urgency to develop investigational microbiome therapeutics for a wide range of conditions linked to a disrupted gut microbiome, the community of microbes that live in our gut, starting with recurrent C. difficile infection, autism spectrum disorder, and inflammatory bowel disease.
To learn more about our work and find out if we are currently recruiting participants for a clinical trial you or a loved one may be interested in, please see below.
Recurrent C. diff
Finch’s lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection (CDI), and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. In June 2020, Finch announced that CP101 met its primary efficacy endpoint in PRISM3, the first of two pivotal trials to support the development of CP101 for the prevention of recurrent CDI. PRISM4, a Phase 3 trial, is designed to serve as the second pivotal trial of CP101 for recurrent CDI.
Autism spectrum disorder
We are developing FIN-211, an investigational orally administered microbiome therapeutic for children with autism and serious gastrointestinal symptoms.
FIN-211 is currently in the pre-clinical development phase, meaning that we have not yet started clinical (in-human) trials to evaluate safety and efficacy. When additional information is available about our trial plans, we will share an update on our website.
Inflammatory bowel disease
In collaboration with Takeda Pharmaceuticals, we are developing investigational orally administered microbiome therapeutics for the treatment of inflammatory bowel disease (IBD).
Our investigational therapeutics for IBD are currently in the pre-clinical development phase, meaning that clinical (in-human) trials to evaluate safety and efficacy have not yet started.